This is a demo store. No orders will be fulfilled.

Sorafenib - ≥99%, high purity , CAS No.284461-73-0, Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of cyclin dependent kinase 19;Inhibitor of cyclin dependent kinase 8;Inhibitor of discoidin domain receptor tyrosine kinase 2;Inhibitor of fibroblast growth factor receptor 1;Inhibitor o

In stock
Item Number
S125098
Grouped product items
SKU Size
Availability
Price Qty
S125098-250mg
250mg
3
$9.90
S125098-1g
1g
3
$19.90
S125098-5g
5g
3
$28.90
S125098-25g
25g
2
$99.90
S125098-100g
100g
2
$279.90

Potent multikinase inhibitor

Basic Description

Synonyms 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide | SCHEMBL8218 | L01XE05 | NSC7177 | UNII-9ZOQ3TZI87 | NSC747971 | NSC-747971 | BAY 439006 | BAY 43-9006 | 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]ca
Specifications & Purity Moligand™, ≥99%
Biochemical and Physiological Mechanisms Sorafenib is a RAF kinase inhibitor which suppresses ERK phosphorylation. Studies indicate that sorafenib induces c-Raf phosphorylation at both Ser-43 and Ser-259. When combined with vitamin K1, phosphorylation is increased at these serine residues. Soraf
Storage Temp Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Grade Moligand™
Action Type INHIBITOR
Mechanism of action Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of cyclin dependent kinase 19;Inhibitor of cyclin dependent kinase 8;Inhibitor of discoidin domain receptor tyrosine kinase 2;Inhibitor of fibroblast growth factor receptor 1;Inhibitor o
Note Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
An inhibitor of tyrosine protein kinases that targets the Raf/Mek/Erk pathway

Taxonomic Classification

Taxonomy Tree

Kingdom Organic compounds
Superclass Organic oxygen compounds
Class Organooxygen compounds
Subclass Ethers
Intermediate Tree Nodes Not available
Direct Parent Diarylethers
Alternative Parents Trifluoromethylbenzenes  N-phenylureas  Pyridinecarboxamides  Phenoxy compounds  Phenol ethers  2-heteroaryl carboxamides  Chlorobenzenes  Aryl chlorides  Heteroaromatic compounds  Ureas  Secondary carboxylic acid amides  Azacyclic compounds  Organopnictogen compounds  Organonitrogen compounds  Organofluorides  Organochlorides  Organic oxides  Hydrocarbon derivatives  Carbonyl compounds  Alkyl fluorides  
Molecular Framework Aromatic heteromonocyclic compounds
Substituents Diaryl ether - Trifluoromethylbenzene - N-phenylurea - Pyridine carboxylic acid or derivatives - Pyridinecarboxamide - 2-heteroaryl carboxamide - Phenoxy compound - Phenol ether - Halobenzene - Chlorobenzene - Benzenoid - Pyridine - Monocyclic benzene moiety - Aryl halide - Aryl chloride - Heteroaromatic compound - Urea - Secondary carboxylic acid amide - Carbonic acid derivative - Carboxamide group - Azacycle - Organoheterocyclic compound - Carboxylic acid derivative - Organic nitrogen compound - Organopnictogen compound - Organic oxide - Hydrocarbon derivative - Organonitrogen compound - Organofluoride - Organochloride - Organohalogen compound - Carbonyl group - Alkyl halide - Alkyl fluoride - Aromatic heteromonocyclic compound
Description This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
External Descriptors aromatic ether - ureas - monochlorobenzenes - (trifluoromethyl)benzenes - pyridinecarboxamide

Associated Targets(Human)

EPHB4 Tchem Ephrin type-B receptor 4 (5 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
DDR2 Tchem Discoidin domain-containing receptor 2 (7 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
EGFR Tclin Epidermal growth factor receptor (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
CSF1R Tclin Macrophage colony-stimulating factor 1 receptor (5 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
CDK8 Tchem Cyclin-dependent kinase 8 (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
CDK19 Tchem Cyclin-dependent kinase 19 (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
DDR1 Tchem Epithelial discoidin domain-containing receptor 1 (4 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
RAF1 Tclin RAF proto-oncogene serine/threonine-protein kinase (19 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
RET Tclin Proto-oncogene tyrosine-protein kinase receptor Ret (14 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
FLT4 Tclin Vascular endothelial growth factor receptor 3 (6 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
EPHX2 Tchem Bifunctional epoxide hydrolase 2 (2 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
HIPK4 Tchem Homeodomain-interacting protein kinase 4 (5 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
FLT3 Tclin Receptor-type tyrosine-protein kinase FLT3 (24 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
FGFR1 Tclin Fibroblast growth factor receptor 1 (2 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
TEK Tclin Angiopoietin-1 receptor (5 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
PDGFRB Tclin Platelet-derived growth factor receptor beta (4 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
BRAF Tclin Serine/threonine-protein kinase B-raf (25 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
ARAF Tchem Serine/threonine-protein kinase A-Raf (3 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
FLT1 Tclin Vascular endothelial growth factor receptor 1 (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
KDR Tclin Vascular endothelial growth factor receptor 2 (33 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
HTR2B Tclin 5-hydroxytryptamine receptor 2B (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
TNNI3K Tchem Serine/threonine-protein kinase TNNI3K (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
KIT Tclin Mast/stem cell growth factor receptor Kit (12 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
MAPK3 Tchem Mitogen-activated protein kinase 3 (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
MAPK14 Tchem Mitogen-activated protein kinase 14 (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
MAP3K20 Tchem Mitogen-activated protein kinase kinase kinase 20 (4 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
ABL1 Tclin Tyrosine-protein kinase ABL (18331 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CA2 Tclin Carbonic anhydrase II (17698 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
INSR Tclin Insulin receptor (5558 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PGR Tclin Progesterone receptor (8562 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AR Tclin Androgen Receptor (11781 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
TOP2A Tclin DNA topoisomerase II alpha (6317 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
IMPDH2 Tclin Inosine-5'-monophosphate dehydrogenase 2 (1326 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
MAOA Tclin Monoamine oxidase A (11911 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HRH2 Tclin Histamine H2 receptor (5428 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AGTR1 Tclin Type-1 angiotensin II receptor (5176 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HRH1 Tclin Histamine H1 receptor (7573 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
GRIN1 Tclin Glutamate (NMDA) receptor subunit zeta 1 (122 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CACNA1C Tclin Voltage-gated L-type calcium channel alpha-1C subunit (766 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PDE3A Tclin Phosphodiesterase 3A (3309 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1711 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PDGFRB Tclin Platelet-derived growth factor receptor beta (5195 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRA2C Tclin Alpha-2c adrenergic receptor (4876 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CHRM3 Tclin Muscarinic acetylcholine receptor M3 (7750 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Associated Targets(non-human)

Cdk4 Cyclin-dependent kinase 4 (3 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Htr7 Serotonin 7 (5-HT7) receptor (19 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Ca7 Carbonic anhydrase VII (3 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Npy1r Neuropeptide Y receptor type 1 (8 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Cckar Cholecystokinin A receptor (90 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PIK3CA PI3-kinase p110-alpha subunit (51 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Pde4d Phosphodiesterase 4D (4 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Pygl Liver glycogen phosphorylase (81 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Prkcd Protein kinase C delta (192 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Prkcb Protein kinase C beta (2 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Hdac1 Histone deacetylase 1 (93 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Fgfr4 Fibroblast growth factor receptor 4 (138 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Fgfr3 Fibroblast growth factor receptor 3 (21 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Camk2g CaM kinase II gamma (1 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Tec Tyrosine-protein kinase TEC (25 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Ulk3 ULK3 kinase (23 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Staphylococcus aureus (210822 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Staphylococcus epidermidis (22802 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Enterococcus faecium (13803 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Enterococcus faecalis (29875 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Plasmodium falciparum (966862 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Rift Valley fever virus (132 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Mus musculus (284745 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Human immunodeficiency virus 1 (70413 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Sindbis virus (1599 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Venezuelan equine encephalitis virus (381 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Hepatitis C virus (23859 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Enterovirus A71 (1246 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
BaF3 (4657 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
C6 (2371 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
H4 (48 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
NIH3T3 (5395 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
H22 (575 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CT26 (928 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AIRC Multifunctional protein ADE2 (8 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
pfk 6-phospho-1-fructokinase (7870 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Eastern equine encephalitis virus (38 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Plasma (328 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Aorta (2975 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Rorc Nuclear receptor ROR-gamma (89407 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
pknB Serine/threonine-protein kinase pknB (356 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CDPK1 Calcium-dependent protein kinase 1 (793 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CRK2 Cell division control protein 2 homolog (194 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Septin9 Septin-9 (1 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Acadvl Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (1 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Chorioallantoic membrane (375 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Thoracic aorta (838 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Names and Identifiers

IUPAC Name 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
INCHI InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChIKey MLDQJTXFUGDVEO-UHFFFAOYSA-N
Smiles CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Isomeric SMILES CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Molecular Weight 464.83
Reaxy-Rn 9666200
Reaxys-RN_link_address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9666200&ln=

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

22 results found

Lot Number Certificate Type Date Item
H2331071 Certificate of Analysis Jun 10, 2025 S125098
H2310058 Certificate of Analysis May 13, 2025 S125098
K2217769 Certificate of Analysis Sep 19, 2024 S125098
K2217770 Certificate of Analysis Sep 19, 2024 S125098
K2217772 Certificate of Analysis Sep 19, 2024 S125098
I2424684 Certificate of Analysis Jun 17, 2024 S125098
B2224283 Certificate of Analysis Dec 20, 2023 S125098
B2224284 Certificate of Analysis Dec 20, 2023 S125098
B2224288 Certificate of Analysis Dec 20, 2023 S125098
E2530003 Certificate of Analysis Dec 19, 2023 S125098
A2403351 Certificate of Analysis Dec 19, 2023 S125098
J2410648 Certificate of Analysis Dec 19, 2023 S125098
A2510053 Certificate of Analysis Dec 19, 2023 S125098
A2403350 Certificate of Analysis Dec 19, 2023 S125098
A2403352 Certificate of Analysis Dec 19, 2023 S125098
A2403353 Certificate of Analysis Dec 19, 2023 S125098
I2426047 Certificate of Analysis Dec 19, 2023 S125098
H2124463 Certificate of Analysis Jun 07, 2023 S125098
K2217767 Certificate of Analysis Oct 26, 2022 S125098
K2217768 Certificate of Analysis Oct 26, 2022 S125098
I2007076 Certificate of Analysis Jul 11, 2022 S125098
B2224281 Certificate of Analysis Dec 24, 2021 S125098

Show more⌵

Chemical and Physical Properties

Solubility Soluble in DMSO (~20 mg/ml), Hot Methanol, DMF (~20 mg/ml), 1:2 solution of DMSO:PBS(PH 7.2 ) (~0.3 mg/ml), 100% ethanol, and ethyl acetate.
Sensitivity heat sensitive;air sensitive
Molecular Weight 464.800 g/mol
XLogP3 4.100
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 7
Rotatable Bond Count 5
Exact Mass 464.086 Da
Monoisotopic Mass 464.086 Da
Topological Polar Surface Area 92.400 Ų
Heavy Atom Count 32
Formal Charge 0
Complexity 646.000
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
The total count of all stereochemical bonds 0
Covalently-Bonded Unit Count 1

Citations of This Product

1. Xi Chen, Ning Zhu, Yajie Wu, Ye Zhang, Yuxuan Zhang, Kaiwen Jin, Zhiyi Zhou, Guang Chen, Jiabing Wang.  (2023)  Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells.  PHYTOMEDICINE,    (155317). 
2. Qinglian Hu, Liwang Xu, Xiaoyu Huang, Yuxuan Duan, Dongchang Sun, Zhengwei Fu, Yunfen Ge.  (2023)  Polydopamine-Modified Zeolite Imidazole Framework Drug Delivery System for Photothermal Chemotherapy of Hepatocellular Carcinoma.  BIOMACROMOLECULES,  24  (12): (5964–5976). 
3. Ye Yuan, Chunyu Tian, Qi Wang, Xinyu Qiu, Yufang Wang, Hulin Jiang, Jifu Hao, Yujing He.  (2023)  Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy.  Advanced Healthcare Materials,    (2301292). 
4. Peifeng Wang, Yang Du, Xingyang Zhao, Yueyang Hu, Tianjun Zhou, Xiaolong Liang, Chihua Fang, Jie Tian.  (2023)  2-Methoxyestradiol loaded mesoporous polydopamine nanoprobes for hypoxia alleviation and sorafenib synergistic treatment of hepatocellular carcinoma.  MATERIALS & DESIGN,  232  (112137). 
5. Yufei Pan, Jing Guan, Yujing Gao, Yuejie Zhu, Huantong Li, Hua Guo, Qianyi He, Zhu Guan, Zhenjun Yang.  (2023)  Modified ASO conjugates encapsulated with cytidinyl/cationic lipids exhibit more potent and longer-lasting anti-HCC effects.  Molecular Therapy-Nucleic Acids,  32  (807-821). 
6. Jing-Qing Le, Fang Yang, Xun-Huan Song, Ke-Ke Feng, Ling-Wu Tong, Meng-Die Yin, Wen-Zhong Zhang, Ying-Qi Lin, Hui Wu, Jing-Wei Shao.  (2023)  A hemoglobin-based oxygen-carrying biomimetic nanosystem for enhanced chemo-phototherapy and hypoxia alleviation of hepatocellular carcinoma.  JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY,  123  (330). 
7. Yao Li, Mengying Liu, Yan Zheng, Zheng Wang, Yanjun Zhao.  (2023)  Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,  641  (135). 
8. Shuai Wang, Jian-Tao Shi, Xing-Rong Wang, Hong-Xia Mu, Xue-Ting Wang, Kai-Yan Xu, Qing-Shan Wang, Shi-Wu Chen.  (2023)  1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism.  BIOORGANIC CHEMISTRY,  133  (106412). 
9. Chunmei Lai, Bingchen Zhang, Dongmiao Li, Xiarong Tan, Bangyue Luo, Jiangwen Shen, Linyan Li, Jingwei Shao.  (2023)  Rational design of a minimum nanoplatform for maximizing therapeutic potency: Three birds with one stone.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,  635  (441). 
10. Hu Xiaomeng, He Yuchao, Han Zhiqiang, Liu Wei, Liu Dongming, Zhang Xihao, Chen Lu, Qi Lisha, Chen Liwei, Luo Yi, Li Qiang, Chen Peng, Wu Qiang, Zhu Xiaolin, Guo Hua.  (2022)  PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma.  Cell Death & Disease,  13  (11): (1-12). 
11. Xing-Rong Wang, Shuai Wang, Hong-Xia Mu, Kai-Yan Xu, Xue-Ting Wang, Jian-Tao Shi, Qi-Hang Cui, Li-Wen Zhang, Shi-Wu Chen.  (2022)  Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer.  EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,  244  (114821). 
12. Wang Chonggao, Cheng Xiaolan, Peng Hao, Zhang Yewei.  (2022)  NIR-Triggered and ROS-Boosted Nanoplatform for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma.  Nanoscale Research Letters,  17  (1): (1-16). 
13. An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen, Ling Dong, Ji-Min Zhu, Yuhao Li.  (2022)  Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma.  Nanomaterials,  12  (18): (3191). 
14. Liyue Zhou, Qiangwei Liang, Yifan Li, Yongjing Cao, Juan Li, Jiayu Yang, Jinxia Liu, Jiawei Bi, Yanhua Liu.  (2022)  Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.  Acta Biomaterialia,  152  (235). 
15. Wenjie Feng, Wanrui Shi, Ze Wang, Yanqi Cui, Xinxin Shao, Shuwei Liu, Li Rong, Yi Liu, Hao Zhang.  (2022)  Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification.  ACS Applied Materials & Interfaces,  14  (33): (37540–37552). 
16. Zaigang Zhou, Jiashe Chen, Yu Liu, Chunjuan Zheng, Wenjuan Luo, Lele Chen, Shen Zhou, Zhiming Li, Jianliang Shen.  (2022)  Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy.  Acta Pharmaceutica Sinica B,  12  (4204). 
17. Chen Zibo, Yuan Tao, Yan Fangjie, Ye Song, Xie Qin, Zhang Bo, Lin Nengmin, He Qiaojun, Yang Bo, Zhu Hong.  (2022)  CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.  BMC CANCER,  22  (1): (1-9). 
18. Yuehua Wang, Zhenjie Wang, Fei Jia, Qing Xu, Zhilin Shu, Junlin Deng, Aimin Li, Meng Yu, Zhiqiang Yu.  (2022)  CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment.  Bioactive Materials,  17  (147). 
19. Jie Cui, Jiatao Liu, Lulu Fan, Yue Zhu, Bei Zhou, Yu Wang, Wei Hua, Wei Wei, Guoping Sun.  (2020)  A zinc finger family protein, ZNF263, promotes hepatocellular carcinoma resistance to apoptosis via activation of ER stress-dependent autophagy.  Translational Oncology,  13  (100851). 
20. Longfa Kou, Rui Sun, Xinyu Jiang, Xinlu Lin, Huirong Huang, Shihui Bao, Youting Zhang, Chao Li, Ruijie Chen, Qing Yao.  (2020)  Tumor Microenvironment-Responsive, Multistaged Liposome Induces Apoptosis and Ferroptosis by Amplifying Oxidative Stress for Enhanced Cancer Therapy.  ACS Applied Materials & Interfaces,  12  (27): (30031–30043). 
21. Haiqiu Wu, Cun Wang, Jiaxin Sun, Luyan Sun, Jiaxun Wan, Siying Wang, Dishui Gu, Chengtao Yu, Chen Yang, Jia He, Zihao Zhang, Yuanyuan Lv, Hui Wang, Ming Yao, Wenxin Qin, Changchun Wang, Haojie Jin.  (2019)  Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis.  ACS Applied Materials & Interfaces,  11  (47): (43996–44006). 
22. Wenhui Gao, Xiaoting Jia, Jinjun Wu, Ying Song, Jiang Yin, Meimei Zhang, Ni Qiu, Xiaoyan Li, Peng Wu, Xiaoxiao Qi, Zhongqiu Liu.  (2019)  Preparation and evaluation of folate-decorated human serum albumin nanoparticles for the targeted delivery of sorafenib to enhance antihepatocarcinoma efficacy.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,  54  (101349). 
23. Lu Bin, Chen Xiao-bing, Hong Yu-cai, Zhu Hong, He Qiao-jun, Yang Bo, Ying Mei-dan, Cao Ji.  (2019)  Identification of PRDX6 as a regulator of ferroptosis.  ACTA PHARMACOLOGICA SINICA,  40  (10): (1334-1342). 
24. Jun-Shan Liu, Chu-Ying Huo, Hui-Hui Cao, Chun-Lin Fan, Jian-Yang Hu, Li-Juan Deng, Zi-Bin Lu, Hua-Yi Yang, Lin-Zhong Yu, Zhi-Xian Mo, Zhi-Ling Yu.  (2019)  Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.  PHYTOMEDICINE,  61  (152843). 
25. Gao Ningning, Zhong Jingjing, Wang Xiaodong, Jin Zhenchao, Li Wang, Liu Yu, Diao Yuwen, Wang Zhulin, Jiang Wenqi, Jin Guangyi.  (2016)  Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.  Scientific Reports,  (1): (1-9). 
26. Ji Cao, Xiaobing Chen, Li Jiang, Bin Lu, Meng Yuan, Difeng Zhu, Hong Zhu, Qiaojun He, Bo Yang, Meidan Ying,.  (2020-03-08)  DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase..  Nature communications,  11  ((1)): ( 1251-1251 ). 
27. Chun-Mei Lai, Jia Xu, Bing-Chen Zhang, Shao-Hua He, Jing-Wei Shao.  (2024)  A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma.  CHEMICAL ENGINEERING JOURNAL,  482  (148976). 
28. Wenlong Huang, Bo Jin, Haobing Gong, Nawab Ali, Duoduo Jiang, Tongtong Shan, Liangshun Zhang, Jia Tian, Weian Zhang.  (2024)  A tumor Microenvironment-triggered protein-binding Near-infrared-II Theranostic nanoplatform for Mild-Temperature photothermal therapy.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,     
29. Taosha Jin, Haiyang Wang, Ihsan Ullah, Wenjiao Xie, Taian Lin, Qiaoling Tan, Xiaoyu Pan, Youyong Yuan.  (2025)  A Wireless Operated Flexible Bioelectronic Microneedle Patch for Actively Controlled Transdermal Drug Delivery.  ADVANCED MATERIALS,    (2417136). 
30. Hongwei Xiang, Bin Shen, Chunmei Zhang, Rui Li.  (2024)  Bioactive Nanoliposomes for Enhanced Sonodynamic-Triggered Disulfidptosis-Like Cancer Cell Death via Lipid Peroxidation.  International Journal of Nanomedicine,     
31. Yuanxin Pian, Yan Hao, Yuxin Guo, Shiqi Wu, Saijiao Tang, Jiaqi Li, Xinya Lu, Xiaoya Sun, Zhaowen Tan, Tianyu Zhu, Yuxiang Tang, Defeng Xu, Hang Hu.  (2025)  Exploration of using α-crocin for drug encapsulation and delivery.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,  106  (106716). 
32. Xiaoxuan Li, Hongyun Zhang, Yufei Deng, Fang qian, Xiaohui Zhang, Shuiping Ding, Xiaoying Hou, Hongzhi Du.  (2024)  Huaier polysaccharides inhibits hepatocellular carcinoma via gut microbiota mediated M2 macrophage polarization.  INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,    (139357). 
33. Yonggang Lv, Zhenghang Chen, Shuai Wang, Meizhen Zou.  (2025)  Macrophage-Mediated Liquid Metal Nanoparticles for Enhanced Tumor Accumulation and Inhibition.  ACS Biomaterials Science & Engineering,     
34. Rui-Rui Zhao, Ju-Hong Wu, Ling-Wu Tong, Jin-Yu Li, Yu-sheng Lu, Jing-Wei Shao.  (2024)  Multifunctional Metal-coordinated Co-assembled Carrier-free Nanoplatform Based on Dual-drugs for Ferroptosis-mediated Cocktail Therapy of Hepatocellular Carcinoma Growth and Metastasis.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,     
35. Fanqi Meng, Lei Chen, Haoran Chen, Meili Shen, Guangyi Wang, Yulei Chang.  (2024)  Multiple Stimuli-Responsive Micelles for Photo/ROS/pH-Triggered Chemo/Photo/Ferroptosis Therapy of Colorectal Cancer.  ACS Applied Nano Materials,  (22): (25995-26005). 
36. Xing Gao, Hongwei Cheng, Minglei Teng, Hongrui Zhang, Hu Chen, Songnan Qu, Gang Liu.  (2025)  Optimizing interventional therapy: A homogeneous lipiodol formulation of Tirapazamine and Sorafenib responsive to post-embolization microenvironment.  JOURNAL OF CONTROLLED RELEASE,  379  (879). 
37. Shunli Yu, Ruhe Zhang, Zhaoxiang Xie, Zhi Xiong, Shirong Peng, Bingheng Li, Ruilin Zhuang, Jun Wu, Hai Huang.  (2024)  Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy.  ACS Biomaterials Science & Engineering,  10  (7): (4336-4346). 
38. Lu-Yao Zheng, Yan-Xin Da, Xiu Luo, Xiao Zhang, Zhi-Jie Sun, De-Li Dong.  (2024)  Sorafenib extends the lifespan of C. elegans through mitochondrial uncoupling mechanism.  FREE RADICAL BIOLOGY AND MEDICINE,  214  (101). 
39. Zhenghao Zhou, Cong Li, Shuai Cui, Shian Sun, Shaowei Zhu, Qing Yu, Ning Ding, Hao Hong, Dongzhi Yang.  (2024)  Synergistic therapy for melanoma via bioactive compounds derived metal-phenolic networks.  CHEMICAL ENGINEERING JOURNAL,  488  (150831). 
40. Chunfang Qin, Hao Wang, Hongyan Cui, Yue Wang, Ming Zhang, Haidong Li, Yuchen Liu, Jingyun Wang, Qixian Chen, Yan Zhao.  (2024)  Synthetic genomic nanomedicine with triple-responsiveness for systemic anti-tumor therapy.  JOURNAL OF COLLOID AND INTERFACE SCIENCE,  672  (350). 
41. Li Xiang, Yuting Qin, Lei Li, Xianjing Xiang, Wenhui Zhang, Qiangqiang Jiao, Yaru Shao, Xinqiong Huang, Meichun Wu, Tianle Zhou, Yukang Lin, Yuping Chen.  (2024)  Targeting hyperactive mitochondria in activated HSCs and inhibition of liver fibrogenesis in mice using sorafenib complex micelles.  INTERNATIONAL JOURNAL OF PHARMACEUTICS,    (125058). 

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.